Pfizer Lifts 2026 Outlook on Eliquis and Cancer Drug Demand, Names New CFO
PFE sits 30% above its 52-week low of $23.62.
Summary
Pfizer raised full-year 2026 revenue guidance to $62.0-64.0 billion from $60.5-62.5 billion and adjusted EPS to $2.95-3.05 from $2.80-3.00, citing strong demand for Eliquis and its cancer drugs. Q3 revenue of $16.58 billion beat the $15.87 billion consensus, and the new EPS midpoint of $3.00 sits above the $2.96 analysts expected. The raise matters because Pfizer is fighting patent cliffs later this decade and has been leaning on deals and licensing to refill the pipeline — better-than-expected base business buys time and credibility for that strategy. Separately, the board named Cecile Guegan CFO effective November 1, filling the seat Dave Denton vacated in August for Nike. Shares are already near a 52-week high, so the guidance hike lands into an optimistic setup rather than a beaten-down one.
At the time of this announcement, PFE was trading at $30.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.8B. The 52-week trading range was $23.62 to $31.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.